Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Again, it’s why a BO wouldn’t happen until after FDA market approval for humans.
Someone correct me if I'm wrong. BO at anytime = level of sp at conclusion of deal + 3× premium, right?
Rdgl is muito better than the bs on the market currently the reason imo why FDA has slow walked RDGL approval because they know and too many other BP with dirty hands....
But the BOOMERANG OF BOOMERANGS is incoming imo to annilhate the lesser competition soon enough lol
Nobody is purchasing a company (that I know of) that hasn’t proven their therapeutics to be safe and effective on humans.. promising product, but in my opinion, they are no where near a BO opportunity… there are currently cancer treatments on the market that are full FDA approved and starting to show revs from their products that are not even being considered for BO yet…
It’s why I said a BO wouldn’t happen until after human trials and FDA grants market approval.
It seems buyouts have been for products/companies that are on the market or at the end of clinical trails (all three phases).
And I’ve noticed the purchased companies are private and easily raising multiple rounds of capital or are public and are already trading on Nasdaq.
My point is, the buyout dollars seem to be focused on finding growth as opposed to funding research. So I think we have a couple stages to move through before the risk/reward is there for a company to make an offer to RDGL.
I’ll be here either way.
I bought 2 lots in May/June timeframe that were above my cost average as well. Went from 277k shares to 328k shares. Cost average went from 9 cents a share to 10.3 cents a share.
I most likely will not buy more shares. 🤞 hoping the market will flood into this ticker upon IDE approval
I think he is thinking 3-5 years down the road, if ever.
Good points! I will dial it back
16's gave me the op to increase my holdings by 20% this a.m. @ .167
Avg went up to .12 but what the hell right been here for 3 yrs and not sold one,ONLY BOUGHT
Vivos Inc. saw a busy June as our quarter came to a close. This is the June summary, the quarterly report will post on the website next week #VivosIncUSA #IsoPet #RadioGel #Cancer #PRnT $RDGL pic.twitter.com/8SrhA7rkN6
— Vivos Inc. (@VivosIncUSA) July 2, 2024
Impatient traders are out but we’re heading into a slow remainder of the week. I think we start heating up next week.
Why would you think it would take a long time? How long are you thinking?
You’ll be waiting long time for a buyout
A buyout after market approval is a possibility. 18-24 months from start of human trials, maybe sooner.
Stop complaining. You have said your cost average is 10 cents. Sell now for a hefty profit and be done. Jeesh. I had a 2 cent average when BDD was submitted and could have sold at 24. Did I bellyache when it dropped back to 5? No, I wait for approval and better things. Nothing happens overnight.
Let's just hope this is the bottom and that we get bought out soon after approval.
The fall from 22 cent to 16 cents has meaning to my account! Just sayin....and no, I'm not selling but also not loving it.
The only reason that this would fall meaningfully is if the IDE gets rejected. Boy , I feel like a genius saying that. Pretty obvious. Otherwise, the floor is in
Well written and glad to see the swingers are gone. There is definitely someone with millions of shares playing games when they sell 22,222 or say 44,444 or 77,777. Must be nice :)
Swing traders and uneducated panic sellers have exited.
Folks shouldn’t have been surprised by the Reg A. It was announced in the 10K from 12/31. MK said he would need to raise funds for the human trials and further expansion etc. That showed a lot of confidence in IDE approval.
The Reg A still needs to be approved and once approved, there won’t be any takers until after IDE approval. And then, offering will be in chunks over time as needed.
IDE approval less than 26 days. High confidence of approval so anyone crying about current share price should be buying more, not selling.
Floor should be in circa .15-.17 area
BOOMERANG BACK AT YOU INCOMING
How did the debate go so far SCOTUS RULINGS LOL
Give it time to digest
Regarding your PM. Will do.
Take care, And good luck.
That's exactly how I would describe most of your posts 😆
Chatgpt is only as good as the information entered into the system....
Like garbage in crap out lol
Knew they were similar in targeted precision while leaving surrounding tissue healthy. Thanks for thorough explanation!
I gave you a follow you're at 9 now😁
The Lilly buyout of Point Biopharma gives us an excellent comparison of what a buyout would look like for Vivos. $1.4b buyout would be about a $3.00 share price for RDGL
### Comparison of Point Biopharma and Vivos Inc. (Radiogel) Products
**Point Biopharma:**
1. **Overview:**
Point Biopharma is a radiopharmaceutical company specializing in radioligand therapies, which combine a radioactive isotope with a targeting molecule to deliver radiation directly to cancer cells. This approach aims to minimize damage to healthy tissues compared to traditional chemotherapy.
2. **Key Products and Pipeline:**
- **PNT2002**: A prostate-specific membrane antigen (PSMA)-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). The Phase 3 SPLASH trial showed significant improvement in radiographic progression-free survival compared to control treatments [oai_citation:1,Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | Eli Lilly and Company](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-point-biopharma-expand-oncology-capabilities-next) [oai_citation:2,Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer](https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/148602-lantheus-and-point-biopharma-announce-positive-topline-results-from-pivotal-splash-trial-in-metastatic-castration-resistant-prostate-cancer.html).
- **PNT2003**: A somatostatin receptor-targeted therapy for neuroendocrine tumors.
- **PNT2004**: Targets fibroblast activation protein-alpha (FAP-a), present in over 90% of solid tumors. It has potential as a monotherapy or in combination with other treatments [oai_citation:3,POINT Biopharma Provides Early-Stage Program Updates](https://www.globenewswire.com/news-release/2022/02/14/2384407/0/en/POINT-Biopharma-Provides-Early-Stage-Program-Updates.html).
3. **Technology and Manufacturing:**
- Point has established a vertically integrated platform, ensuring control over the development, manufacturing, and delivery of radiopharmaceuticals. This includes securing supplies of critical isotopes like actinium-225 and lutetium-177 [oai_citation:4,Creating the platform for next-generation radiopharmaceuticals](https://www.nature.com/articles/d43747-022-00052-2).
- The company’s Indianapolis facility is capable of serving North America and beyond, allowing for on-demand manufacturing and rapid distribution to clinics [oai_citation:5,Creating the platform for next-generation radiopharmaceuticals](https://www.nature.com/articles/d43747-022-00052-2).
**Vivos Inc. (Radiogel):**
1. **Overview:**
Vivos Inc. develops Radiogel, a minimally invasive injectable treatment designed to deliver high-dose radiation directly to cancerous tissues. The product uses a water-based gel to encapsulate radioactive particles, allowing for localized radiation therapy.
2. **Key Products and Pipeline:**
- **Radiogel™**: An injectable hydrogel that delivers yttrium-90, a beta-emitting radioisotope, directly into tumors. This method aims to provide precise radiation therapy with minimal exposure to surrounding healthy tissues.
- **IsoPet®**: A veterinary version of Radiogel, used for treating solid tumors in animals.
3. **Technology and Manufacturing:**
- Radiogel is designed to be a highly localized treatment option, reducing the need for extensive systemic radiation therapy. It is particularly suited for solid tumors where precise radiation delivery is crucial.
- The product leverages the physical properties of hydrogels to retain the radioactive isotopes at the tumor site, thus minimizing the spread of radiation to other body parts.
### Summary:
- **Point Biopharma** focuses on radioligand therapies, using isotopes like lutetium-177 and actinium-225 to treat various cancers, with a strong emphasis on precision targeting and minimizing side effects. Their advanced manufacturing capabilities support rapid production and distribution.
- **Vivos Inc.'s Radiogel** provides a localized radiation therapy option through injectable hydrogels, focusing on delivering high-dose radiation directly to tumors while sparing healthy tissues. It is currently available in both human and veterinary versions.
Both companies represent innovative approaches in the field of radiopharmaceuticals, aiming to improve the precision and effectiveness of cancer treatments while reducing adverse effects.
Wonder how their products compare to ours?🤔
Disturbingly dumb yes I like that . I've concluded that the selling is from traders especially at these prices that were going to sell anyway after submission and not take it through the process . I also figure those same folks may not have looked very closely at the meticulous work and 2.5 yearsof painstakingly care put into the submission .
So be it
MMs, feed me, I’m hungry for more RDGL
selling at this level is disturbingly dumb
where do you think the price will be 2-3 days before the 30 day window deadline? sure as fuck isn’t going to be way down here
Only 60 million shares, and it's baked into the price?
Let's agree to disagree. I believe the market will keep it near 15 cents until IDE.
This is exactly why I would moan about running out of funds because of needless spending on IsoPet. We would have been much better off, imo, if we had zero additional vet clinics opened and zero IsoPet effort outside support for RadioGel over the past 2+ years. Likely, we could have made it here without that last need for capital raise (maybe last 2), then they could have waited for IDE approval, see where stock price is after IDE, and sell fewer shares at a higher price than what we have to sell for now at that time.
Everyone keeps talking about buy-out by BP. A buyout for a company at 5 billion dollars for a company with 380 million shares is $13/share. Same buyout for a company with 480 million shares is $10/share. You have done nicely either way...but one needs these kinds of buyout levels for impact to be minimal.
It is hard to keep spirits up while seeing the price action lately. One can try to focus on the company's target of treating all solid cancerous tumors - it is certainly possible they get there ($5B bouout). I would even say probable if IDE is approved and our 1st clinical trials go well.
✌️ Waiting for 🚀 but until then it's 🤷🏻♂️🤯😳😞. Hopefully once IDE is approved we will all 💣💥🚀🤩🎉🎊🍾🍺🍺🤑🤑🤌🍾🍾🍾🎉🎉🍾🍾
I'm noticing who sold or trimmed heavily and are now attempting to influence the stock . Over the 20 years on the hub I see it and I recognize it .
No class traders is my label
Next week knocks the wait time down to 3 weeks max
That detail needs to be ignored for now as hard as that may be and as catfish stated it isn't approved yet and won't be until after submission approval
Where jmo entities with larger cash reserves thsn we have previously seen waiting for that approval will move into the stock .
Next will be the move to begin human trials and again entities with large cash will have done some extensive DD and realized this phase 1 trial for thyroid tumors is likely to be slam dunk event
Meanwhile that 15 cent offering may or may not be adjusted higher but any rate it will be sold out and buyers will realize the only way to make enormous future profits is to buy the stock
This current MC should be an embarrassment to management/korenko but I doubt its going to remain like this for long
I get your POV WALLnut. However, speculations on stock message boards is not unique to RDGL ihub. It is worse in all tickers even in GME on Yahoo and stocktwits. It is what it is and a part of the culture I guess. Let no one lie to anyone as if it is something unique to RDGL board. This is not to discount MM roles in the marketplace, I'm just of the view that no one needs to tremble or worry at the mention of them.
Stickers.
This news came later on Friday. We already had 4 red days prior to so it cant be factored in. And its only 60 mill shares. BFD.
Oh, I believe we'll hit bottom. Not worried about that. But at this point, we really shouldn't be looking at a bottom, should be looking at new daily highs. Many new eyes here, a few great articles released, IDE submitted and company tweeting up a storm compared to past. So yeah, no real reason to have 5 red days of 6.
Market is also factoring in 60 million new shares at 15 cents....
Vivos is treating cancer successfully. We should be selling Reg A shares at a minimum .50 not .15.
WALLnut, you are the most realistic on here. We are all investors in RDGL And have big hopes.. hope in one hand an @#$& in the other, lol. I at least hope we have hit a bottom in the pps and the bleedingg stops
The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
What are the advantages of RadioGel™?
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
What is the market for RadioGel™?
Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.
What is Brachytherapy?
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.
Are there other markets for RadioGel™?
March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.
The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
What are the steps for FDA clearance?
Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.
August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018, Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
Press Releases 2017 ( Change in Management & Directors Dec 2016)
Dec 20, 2016, AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017, AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017, AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017, AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017, AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017, Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017, AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017, ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017, ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017, Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017, Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™
Independent Analyst Research and Price Target
Presentation(s) from CEO & President, Dr. Mike Korenko.
2017 - LINK HERE
STOCK SYMBOL: OTC: RDGL
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |